Olivia Joan Makinson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Olivia Joan Makinson has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- David P. Cook
Cancer Research Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada
2 shared publications - Jonathan J. Hodgins
Department of Research Biology, Genentech Research and Early Development, South San Francisco, USA
2 shared publications - Marie Marotel
Cancer Research Ottawa Hospital Research Institute Ottawa ON Canada
2 shared publications - Michele Ardolino
Department of Biochemistry, Immunology and Microbiology, University of Ottawa, Ottawa, ON K1H 8M5, Canada
2 shared publications Alessandra Zingoni
Department of Molecular Medicine, Sapienza University of Rome, Laboratory affiliated to Istituto Pasteur Italia—Fondazione Cenci-Bolognetti, Rome, Italy
1 shared publication- Amit K. Scheer
Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada
1 shared publication
Latest Publications
- Open Access
- 13 June 2024
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 221 (7)
PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathway
While conventional wisdom initially postulated that PD-L1 serves as the inert ligand for PD-1, an emerging body of literature suggests that PD-L1 has cell-intrinsic functions in immune and cancer cells. In line with these studies, here we show that engagement of PD-L1 via cellular ligands or agonistic antibodies, including those used in the clinic, potently inhibits the type I interferon pathway in cancer cells. Hampered type I interferon responses in PD-L1–expressing cancer cells resulted in enhanced efficacy of oncolytic viruses in vitro and in vivo. Consistently, PD-L1 expression marked tumor explants from cancer patients that were best infected by oncolytic viruses. Mechanistically, PD-L1 promoted a metabolic shift characterized by enhanced glycolysis rate that resulted in increased lactate production. In turn, lactate inhibited type I IFN responses. In addition to adding mechanistic insight into PD-L1 intrinsic function, our results will also help guide the numerous ongoing efforts to combine PD-L1 antibodies with oncolytic virotherapy in clinical trials.
- 13 June 2024
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 221 (7)
Open AccessPD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathway
While conventional wisdom initially postulated that PD-L1 serves as the inert ligand for PD-1, an emerging body of literature suggests that PD-L1 has cell-intrinsic functions in immune and cancer cells. In line with these studies, here we show that engagement of PD-L1 via cellular ligands or agonistic antibodies, including those used in the clinic, potently inhibits the type I interferon pathway in cancer cells. Hampered type I interferon responses in PD-L1–expressing cancer cells resulted in enhanced efficacy of oncolytic viruses in vitro and in vivo. Consistently, PD-L1 expression marked tumor explants from cancer patients that were best infected by oncolytic viruses. Mechanistically, PD-L1 promoted a metabolic shift characterized by enhanced glycolysis rate that resulted in increased lactate production. In turn, lactate inhibited type I IFN responses. In addition to adding mechanistic insight into PD-L1 intrinsic function, our results will also help guide the numerous ongoing efforts to combine PD-L1 antibodies with oncolytic virotherapy in clinical trials.
- Open Access
- 15 April 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (15) , eabj3286
When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer
Trogocytosis modulates immune responses, with still unclear underlying molecular mechanisms. Using leukemia mouse models, we found that lymphocytes perform trogocytosis at high rates with tumor cells. While performing trogocytosis, both Natural Killer (NK) and CD8 + T cells acquire the checkpoint receptor PD-1 from leukemia cells. In vitro and in vivo investigation revealed that PD-1 on the surface of NK cells, rather than being endogenously expressed, was derived entirely from leukemia cells in a SLAM receptor–dependent fashion. PD-1 acquired via trogocytosis actively suppressed NK cell antitumor immunity. PD-1 trogocytosis was corroborated in patients with clonal plasma cell disorders, where NK cells that stained for PD-1 also stained for tumor cell markers. Our results, in addition to shedding light on a previously unappreciated mechanism underlying the presence of PD-1 on NK and cytotoxic T cells, reveal the immunoregulatory effect of membrane transfer occurring when immune cells contact tumor cells.
- 15 April 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (15) , eabj3286
Open AccessWhen killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer
Trogocytosis modulates immune responses, with still unclear underlying molecular mechanisms. Using leukemia mouse models, we found that lymphocytes perform trogocytosis at high rates with tumor cells. While performing trogocytosis, both Natural Killer (NK) and CD8 + T cells acquire the checkpoint receptor PD-1 from leukemia cells. In vitro and in vivo investigation revealed that PD-1 on the surface of NK cells, rather than being endogenously expressed, was derived entirely from leukemia cells in a SLAM receptor–dependent fashion. PD-1 acquired via trogocytosis actively suppressed NK cell antitumor immunity. PD-1 trogocytosis was corroborated in patients with clonal plasma cell disorders, where NK cells that stained for PD-1 also stained for tumor cell markers. Our results, in addition to shedding light on a previously unappreciated mechanism underlying the presence of PD-1 on NK and cytotoxic T cells, reveal the immunoregulatory effect of membrane transfer occurring when immune cells contact tumor cells.